These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

158 related articles for article (PubMed ID: 7647342)

  • 21. Oestrogen receptor/progesterone receptor and human epidermal growth factor receptor 2 status in breast cancer: a 9-year study at Princess Noorah Oncology Center, Saudi Arabia.
    Satti MB
    Histopathology; 2011 Sep; 59(3):537-42. PubMed ID: 21668473
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The immunohistochemically "ER-negative, PR-negative, HER2-negative, CK5/6-negative, and HER1-negative" subgroup is not a surrogate for the normal-like subtype in breast cancer.
    Yu KD; Shen ZZ; Shao ZM
    Breast Cancer Res Treat; 2009 Dec; 118(3):661-3. PubMed ID: 19714461
    [No Abstract]   [Full Text] [Related]  

  • 23. Estrogen and progesterone receptor and c-erbB-2 oncoprotein analysis in pure in situ breast carcinoma: an immunohistochemical study.
    Wilbur DC; Barrows GH
    Mod Pathol; 1993 Mar; 6(2):114-20. PubMed ID: 8097877
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Correlations between HER2 Expression and Other Prognostic Factors in Breast Cancer: Inverse Relations with the Ki-67 Index and P53 Status.
    Payandeh M; Shahriari-Ahmadi A; Sadeghi M; Sadeghi E
    Asian Pac J Cancer Prev; 2016; 17(3):1015-8. PubMed ID: 27039719
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Evaluation of the Expression of Amine Oxidase Proteins in Breast Cancer.
    Sun WY; Choi J; Cha YJ; Koo JS
    Int J Mol Sci; 2017 Dec; 18(12):. PubMed ID: 29261141
    [TBL] [Abstract][Full Text] [Related]  

  • 26. PIK3CA mutations correlate with hormone receptors, node metastasis, and ERBB2, and are mutually exclusive with PTEN loss in human breast carcinoma.
    Saal LH; Holm K; Maurer M; Memeo L; Su T; Wang X; Yu JS; Malmström PO; Mansukhani M; Enoksson J; Hibshoosh H; Borg A; Parsons R
    Cancer Res; 2005 Apr; 65(7):2554-9. PubMed ID: 15805248
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Expression and mutational analysis of GATA3 in Malaysian breast carcinomas.
    Bong PN; Zakaria Z; Muhammad R; Abdullah N; Ibrahim N; Emran NA; Syed Hussain SN
    Malays J Pathol; 2010 Dec; 32(2):117-22. PubMed ID: 21329183
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Invasive micropapillary carcinoma of the breast: a clinicopathologic study of 103 cases of an unusual and highly aggressive variant of breast carcinoma.
    Gokce H; Durak MG; Akin MM; Canda T; Balci P; Ellidokuz H; Demirkan B; Gorken IB; Sevinc AI; Kocdor MA; Saydam S; Harmancioglu O
    Breast J; 2013; 19(4):374-81. PubMed ID: 23714006
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Correlation of erbB-2 gene amplification with low levels of estrogen and/or progesterone receptors in primary breast cancer: do erbB-2 products delineate hormone-independent tumors?
    Roux-Dosseto M; Romain S; Dussault N; Martin PM
    Biomed Pharmacother; 1989; 43(9):641-9. PubMed ID: 2696563
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Prognostic significance of HER-2/neu oncoprotein expression in node-positive breast cancer. The influence of the pattern of immunostaining and adjuvant therapy.
    Têtu B; Brisson J
    Cancer; 1994 May; 73(9):2359-65. PubMed ID: 7909490
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Immunohistochemical heterogeneity of breast carcinomas negative for estrogen receptors, progesterone receptors and Her2/neu (basal-like breast carcinomas).
    Rakha EA; Ellis IO; Reis-Filho JS
    Mod Pathol; 2008 Aug; 21(8):1060-1; author reply 1061-2. PubMed ID: 18654595
    [No Abstract]   [Full Text] [Related]  

  • 32. Expression of metastasis-related nm23-H1 and nm23-H2 genes in ovarian carcinomas: correlation with clinicopathology, EGFR, c-erbB-2, and c-erbB-3 genes, and sex steroid receptor expression.
    Mandai M; Konishi I; Koshiyama M; Mori T; Arao S; Tashiro H; Okamura H; Nomura H; Hiai H; Fukumoto M
    Cancer Res; 1994 Apr; 54(7):1825-30. PubMed ID: 7907945
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Correlation of immunohistochemical expression of p53 with unamplified chromosome 17 polysomy in invasive breast carcinoma.
    Krishnamurti U; Zarineh A; Atem FD; Silverman JF
    Appl Immunohistochem Mol Morphol; 2011 Jan; 19(1):28-32. PubMed ID: 20823770
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Levels of hypoxia-inducible factor-1alpha independently predict prognosis in patients with lymph node negative breast carcinoma.
    Bos R; van der Groep P; Greijer AE; Shvarts A; Meijer S; Pinedo HM; Semenza GL; van Diest PJ; van der Wall E
    Cancer; 2003 Mar; 97(6):1573-81. PubMed ID: 12627523
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Immunohistochemical evaluation of human epidermal growth factor receptor 2 and estrogen and progesterone receptors in breast carcinoma in Jordan.
    Almasri NM; Al Hamad M
    Breast Cancer Res; 2005; 7(5):R598-604. PubMed ID: 16168103
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Two histopathologically different diseases: hormone receptor-positive and hormone receptor-negative tumors in HER2-positive breast cancer.
    Lee HJ; Park IA; Park SY; Seo AN; Lim B; Chai Y; Song IH; Kim NE; Kim JY; Yu JH; Ahn JH; Gong G
    Breast Cancer Res Treat; 2014 Jun; 145(3):615-23. PubMed ID: 24820412
    [TBL] [Abstract][Full Text] [Related]  

  • 37. c-erbB-2 protein overexpression and p53 immunoreaction in primary and recurrent breast cancer tissues.
    Shimizu C; Fukutomi T; Tsuda H; Akashi-Tanaka S; Watanabe T; Nanasawa T; Sugihara K
    J Surg Oncol; 2000 Jan; 73(1):17-20. PubMed ID: 10649273
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Factors influencing the hormone receptor and HER2 levels in breast cancer: a population-based analysis.
    Tas F
    Onkologie; 2012; 35(3):95-8. PubMed ID: 22414972
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Epidermal growth factor receptor and vascular endothelial growth factor receptor 2 are specific biomarkers in triple-negative breast cancer. Results from a controlled randomized trial with long-term follow-up.
    Rydén L; Jirström K; Haglund M; Stål O; Fernö M
    Breast Cancer Res Treat; 2010 Apr; 120(2):491-8. PubMed ID: 20135347
    [TBL] [Abstract][Full Text] [Related]  

  • 40. p53 and c-erbB-2 protein expression in breast carcinomas. An immunohistochemical study including correlations with receptor status, proliferation markers, and clinical stage in human breast cancer.
    Barbareschi M; Leonardi E; Mauri FA; Serio G; Dalla Palma P
    Am J Clin Pathol; 1992 Oct; 98(4):408-18. PubMed ID: 1357956
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.